close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

173.97 -4.04 (-2.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Meet the Biotech Stock That Just Jumped 251% Higher
Find out what sent this typically overlooked stock through the roof. 
Via The Motley Fool
Revolution Medicines, Disc Medicine, American Express And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win
Wall Street boosted the stock’s price targets after the company’s late-stage trial for its essential tremor drug, ulixacaltamide, delivered strong efficacy and safety data. 
Via Stocktwits
Topics Death
Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?
Via Stocktwits
Earnings Scheduled For August 4, 2025
 
Via Benzinga
What to Expect from Praxis Precision Medicine's Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Dow Dips Over 100 Points; US Crude Oil Inventories Surge
 
Via Benzinga
Topics Stocks
The 'Groundbreaking' Results That Sent Praxis Precision Medicines Up 200%
The company is working on a treatment for essential tremor. Positive results shocked investors following a negative readout in February. 
Via Investor's Business Daily
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts
 
Via Benzinga
The Analyst Verdict: Praxis Precision Medicine In The Eyes Of 4 Experts
 
Via Benzinga
Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Stay updated with the stocks that are on the move in today's pre-market session.
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Praxis Precision Medicines Stock Doubles - Here's Why
Praxis stock jumps after Phase 3 trials show ulixacaltamide significantly improves essential tremor symptoms and meets key efficacy endpoints. 
Via Benzinga
Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures
Praxis Precision Medicines stock fluctuated after reporting mixed results for their drug vormatrigine in treating focal onset seizures. 
Via Benzinga
Praxis (PRAX) Q2 Loss Widens 90%
Via The Motley Fool
Praxis Precision Medicines (NASDAQ:PRAX) Posts Q2 2025 Results with Strong Clinical Progress on Vormatrigine
Praxis Precision Medicines (PRAX) reports Q2 2025 results, highlighting strong clinical data for epilepsy drug vormatrigine with 56.3% seizure reduction. EPS beats estimates, stock rises pre-market. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
Chardan initiates Praxis with a Buy rating, highlighting its epilepsy pipeline, strong cash position, and billion-dollar potential of vormatrigine. 
Via Benzinga
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Assessing Praxis Precision Medicine: Insights From 8 Financial Analysts
 
Via Benzinga
Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings)
 
Via Benzinga
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate
Praxis Precision Medicines' ulixacaltamide study for essential tremor faces setback as IDMC recommends stopping for futility. Topline results expected in Q3 2025. 
Via Benzinga
Keep an eye on the top gainers and losers in Friday's session.
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements. 
Via Chartmill
Friday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
These stocks are gapping in today's session
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today